NCT06358508 - Sapphire 3 CTO Study | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Coronary Artery DiseaseCoronary DiseaseMyocardial IschemiaHeart DiseasesArteriosclerosisCardiovascular DiseasesChronic Total OcclusionChronic Total Occlusion of Coronary Artery

Interventions

DEVICE

Sapphire 3 Coronary Dilatation Catheter

To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.

Trial Locations (14)

30033

RECRUITING

Atlanta VA Health Care System, Decatur

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30309

RECRUITING

Piedmont Heart Institute, Atlanta

30322

RECRUITING

Emory University Hospital, Atlanta

30342

RECRUITING

Emory St. Joseph's Hospital, Atlanta

47003

RECRUITING

Hospital Clinico Universitario de Valladolid, Valladolid

48202

RECRUITING

Henry Ford Health System, Detroit

55407

RECRUITING

Minneapolis Heart Institute Foundation, Minneapolis

90505

RECRUITING

Torrance Memorial Medical Center, Torrance

94305

RECRUITING

Stanford Health Care, Stanford

98195

RECRUITING

University of Washington, Seattle

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Brigham and Women's Hospital Heart and Vascular Center, Boston

08907

RECRUITING

Hospital Universitari de Bellvitge, Barcelona